Lung Association Brings Attention to Early Cancer Detection

In order to raise awareness around a new early-detection lung cancer screening, the American Lung Association launched a new campaign.

Using video, print ads, a quiz, and other tactics, the American Lung Association’s LUNG FORCE initiative and the Ad Council are encouraging at-risk individuals to undergo a new early-detection lung cancer screening.

“The reason that the lung association is doing this is that lung cancer is the number-one cancer killer of both men and women in the U.S.,” said Jeff Seyler, ALA Executive Vice President, Northeast Region. “It takes more life than any other cancer, which a lot of people aren’t aware of. And one reason why lung cancer is so deadly is because it’s often diagnosed at a later stage, and at that point, there are fewer treatment options available. So being screened early is really critical to increasing the survival rate and the options for treatment.”

The Saved by the Scan campaign, which kicked off on World Lung Cancer Day on August 1 with representatives from ALA and the Ad Council ringing the Nasdaq bell, focuses on the low-dose CT scan that can detect lung cancer before symptoms appear. Through the use of video, social media, print and outdoor ads, and a quiz that helps people determine if they’re eligible for the scan, it aims to drive the 9 million high-risk individuals in the U.S. to get tested.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Oncimmune Holdings PLC

    More articles like this

    Oncimmune Holdings report two further ImmunoINSIGHTS contracts signed

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, today announced the signing of two new ImmunoINSIGHTS commercial contracts. The first contract is with an US-based clinical-stage biopharmaceutical company which is developing first-in-class cellular immunotherapies for cancer

    Oncimmune signs new commercial follow-on contract 

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a new commercial follow-on contract with a world-leading medical research organisation based in the US, to validate the findings from a previous

    Oncimmune signs go-to-market partnership with Synexa Life Sciences

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a go-to-market partnership with Synexa Life Sciences BV, a global leader in biomarker and bioanalytical science, focused on delivering a range of biomarker

    Oncimmune signs new commercial contract with Verily Life Sciences 

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a new commercial contract with Verily Life Sciences LLC, an Alphabet company (parent company to Google), focusing on the autoantibody profiling of patients

    Oncimmune Holdings Notice of half year results

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has stated today that it will be announcing its half year results for the six months ended 30 November 2021 on 28 February 2022. ImmunoINSIGHTS Service Business Oncimmune

    Oncimmune achieves FY2021 revenue of £3.7 million

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced its audited results for the year ended 31 May 2021 and provides an update on recent progress and the outlook for the current financial year.

    Oncimmune to evaluate the profile of patients using ImmunoINSIGHTS

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced it has signed an autoantibody profiling agreement with a leading global pharmaceutical company to evaluate the autoantibody profiles of patient samples in various autoimmune diseases. The